AB Science receives FDA and EMA authorization for phase 3 Trial of prostate cancer treatment
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Subscribe To Our Newsletter & Stay Updated